TFRC and early-onset autosomal dominant Alzheimer disease: Bispecific antibodies, with one domain targeting the transferrin receptor at high affinity and the other domain directed towards a putative therapeutic target relevant for treating Alzheimer’s disease, i.e., beta-secretase 1, lead to reduction of amyloidogenic peptide formation in the brain [41].